New drugs in the US were, on average, approved months before winning approval in the EU, according to new data from The IQVIA ...

Another trial for SIGA Technologies' mpox antiviral has failed, and all enrollment has been stopped, the NIH's National ...

Candel Therapeutics’ viral immunotherapy candidate passed a late-stage test in certain patients with prostate cancer, sending ...

UnitedHealthcare CEO Brian Thompson's shooting death sparked public discussion about healthcare industry frustration. The ...

Relay Therapeutics’ stock {$RLAY} rose about 6% on Wednesday morning after it released positive interim data for its PI3Kα ...

Companies Beam Therapeutics and Prime Medicines presented research on reducing chemotherapy in gene therapy conditioning, ...

Ace­lyrin is of­fi­cial­ly end­ing de­vel­op­ment of an ex­per­i­men­tal med­i­cine it re­ferred to as a “ di­a­mond in the ...

Through a new relationship with Eli Lilly, Ro patients can now get easier access to the drugmaker’s discounted, single-dose ...

Data from a Phase 3 study in second-line breast cancer showed that Eli Lilly’s oral SERD reduced the risk of progression or ...

Moberg Pharma's Terclara fails Phase 3 trial for fungal nail infection maintenance dosing; Bayer exits partnership and ...

After a mid-stage failure in atopic dermatitis, Q32 Bio plans to take bempikibart forward in alopecia instead, despite a trial in that indication also coming apart due to an error in patient ...

A survey of 77 biotech executives reveals concerns about FDA changes following Donald Trump's reelection. Martin Makary's ...